Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM Extension cross-over group.
Aged
Aged, 80 and over
Bone Density
/ drug effects
Bone Density Conservation Agents
/ administration & dosage
Cortical Bone
/ drug effects
Cross-Over Studies
Denosumab
/ administration & dosage
Double-Blind Method
Drug Administration Schedule
Female
Follow-Up Studies
Forearm Injuries
/ prevention & control
Humans
Humeral Fractures
/ prevention & control
Injections, Subcutaneous
Middle Aged
Osteoporosis, Postmenopausal
/ drug therapy
Osteoporotic Fractures
/ prevention & control
Radius
/ physiopathology
Wrist Injuries
/ prevention & control
BMD
Denosumab
Fractures
Osteoporosis
Journal
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
ISSN: 1433-2965
Titre abrégé: Osteoporos Int
Pays: England
ID NLM: 9100105
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
20
07
2018
accepted:
15
05
2019
pubmed:
16
6
2019
medline:
11
2
2020
entrez:
16
6
2019
Statut:
ppublish
Résumé
Upper limb fractures (including wrist, forearm, and humerus) represent a significant burden among postmenopausal women with osteoporosis. Up to 7 years of treatment with denosumab resulted in an increase in bone mineral density and decrease in fractures in upper limb sites. Upper limb (wrist, forearm, and humerus) fractures are a significant burden in osteoporosis, associated with significant morbidity and mortality. Denosumab, a monoclonal antibody against RANK ligand, increases bone mineral density (BMD) and decreases vertebral, nonvertebral, and hip fractures. Here, we evaluated the long-term effect of denosumab treatment on upper limb fracture risk and BMD. In the FREEDOM trial, subjects were randomized 1:1 to receive every-6-month denosumab 60 mg or placebo subcutaneously for 3 years, after which all subjects could receive denosumab for up to 7 years (Extension). Among placebo subjects who completed FREEDOM and enrolled in the Extension, wrist, forearm, humerus, and upper limb fracture rates and rate ratios between different time periods (FREEDOM years 1-3, Extension years 1-3, and Extension years 4-7) were computed. BMD at the ultradistal radius, 1/3 radius, and total radius was analyzed in a subset of subjects in a BMD substudy. This analysis included 2207 subjects (116 in the BMD substudy). Fracture rates decreased over the 7-year Extension; fracture rate ratios between Extension years 4-7 (denosumab) and FREEDOM years 1-3 (placebo) reduced significantly for the wrist (0.57), forearm (0.57), humerus (0.42), and upper limb (0.52; p < 0.05 for all). Percentage increase in BMD from Extension baseline at the ultradistal radius, 1/3 radius, and total radius was significant by Extension year 7 (p < 0.05 for all). Long-term treatment with denosumab decreases upper limb fracture risk and increases forearm BMD, suggesting beneficial effects on both cortical and trabecular bone accruing over time.
Identifiants
pubmed: 31201481
doi: 10.1007/s00198-019-05020-8
pii: 10.1007/s00198-019-05020-8
pmc: PMC6719332
doi:
Substances chimiques
Bone Density Conservation Agents
0
Denosumab
4EQZ6YO2HI
Types de publication
Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
1855-1864Références
Lancet. 1999 Mar 13;353(9156):878-82
pubmed: 10093980
Osteoporos Int. 1999;9(6):469-75
pubmed: 10624452
J Clin Endocrinol Metab. 2000 Apr;85(4):1492-7
pubmed: 10770187
J Bone Miner Res. 2000 Apr;15(4):721-39
pubmed: 10780864
J Clin Endocrinol Metab. 2000 Nov;85(11):4118-24
pubmed: 11095442
Am J Epidemiol. 2001 Mar 15;153(6):587-95
pubmed: 11257067
N Engl J Med. 2001 May 10;344(19):1434-41
pubmed: 11346808
Arch Intern Med. 2004 May 24;164(10):1108-12
pubmed: 15159268
J Bone Miner Res. 2005 Feb;20(2):185-94
pubmed: 15647811
Osteoporos Int. 2006 Dec;17(12):1726-33
pubmed: 16983459
JAMA. 2006 Dec 27;296(24):2927-38
pubmed: 17190893
Pharmacotherapy. 2007 Jun;27(6):779-88
pubmed: 17542760
Cochrane Database Syst Rev. 2008 Jan 23;(1):CD001155
pubmed: 18253985
J Bone Miner Res. 2009 Jan;24(1):153-61
pubmed: 18767928
J Bone Miner Res. 2010 Jan;25(1):72-81
pubmed: 19594293
N Engl J Med. 2009 Aug 20;361(8):756-65
pubmed: 19671655
J Bone Miner Res. 2010 Aug;25(8):1886-94
pubmed: 20222106
Bone. 2010 Jul;47(1):131-9
pubmed: 20399288
Bone. 2011 Apr 1;48(4):677-92
pubmed: 21145999
Osteoporos Int. 2011 Sep;22(9):2439-48
pubmed: 21161507
J Clin Densitom. 2013 Apr-Jun;16(2):147-53
pubmed: 22521543
Menopause. 2013 Feb;20(2):130-7
pubmed: 23010883
Osteoporos Int. 2013 Mar;24(3):811-23
pubmed: 23306819
Bone. 2014 Feb;59:173-9
pubmed: 24275677
Osteoporos Int. 2014 May;25(5):1439-43
pubmed: 24577348
J Bone Miner Res. 2015 May;30(5):934-44
pubmed: 25545380
Osteoporos Int. 2015 Dec;26(12):2763-71
pubmed: 26068295
J Clin Endocrinol Metab. 2016 Aug;101(8):3163-70
pubmed: 27270237
Ther Adv Musculoskelet Dis. 2016 Dec;8(6):225-235
pubmed: 28255336
Lancet Diabetes Endocrinol. 2017 Jul;5(7):513-523
pubmed: 28546097
Ann Chir Gynaecol. 1988;77(1):27-31
pubmed: 3207343
N Engl J Med. 1995 Mar 23;332(12):767-73
pubmed: 7862179
Calcif Tissue Int. 1993 Apr;52(4):269-72
pubmed: 8467406
Osteoporos Int. 1993 May;3(3):133-7
pubmed: 8481589
Lancet. 1996 Dec 7;348(9041):1535-41
pubmed: 8950879
JAMA. 1998 Dec 23-30;280(24):2077-82
pubmed: 9875874